The Department of War’s Office of Strategic Capital has signed an 80 million dollar conditional loan commitment with Antheia, the biosynthesis company, to support domestic manufacturing of key starting materials and active pharmaceutical ingredients for essential generic medicines, the department announced. The vast majority of those inputs are currently manufactured outside the United States.
Antheia’s process uses bioengineered yeast to convert sugar directly into pharmaceutical starting materials and active ingredients through fermentation, an alternative to conventional chemical synthesis and to agriculture dependent supply chains for plant derived compounds. The commitment, alongside additional private capital, is intended to help the company establish manufacturing operations in the United States.
The conditional label carries the substance. The 80 million dollars is not disbursed funding: Antheia must satisfy financial, legal, technical, investment and due diligence requirements before the loan can reach financial close. Readers should not add it to the more than 175 million dollars of equity and other capital the company said it secured over the past year in its Series C financing.
The deal extends the Office of Strategic Capital’s pattern of using defence balance sheet tools for civilian supply chain bottlenecks, in this case the ingredient layer of the generic drug supply, where a single offshore disruption can idle finished medicine production.